• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

GM-CSF overexpression after influenza a virus infection prevents mortality and moderates M1-like airway monocyte/macrophage polarization

tetano

Editor, Senior Moderator
Respir Res. 2018 Jan 5;19(1):3. doi: 10.1186/s12931-017-0708-5.
[h=1]GM-CSF overexpression after influenza a virus infection prevents mortality and moderates M1-like airway monocyte/macrophage polarization.[/h] Halstead ES[SUP]1,[/SUP][SUP]2[/SUP], Umstead TM[SUP]3,[/SUP][SUP]4[/SUP], Davies ML[SUP]3,[/SUP][SUP]4[/SUP], Kawasawa YI[SUP]5[/SUP], Silveyra P[SUP]3,[/SUP][SUP]4[/SUP], Howyrlak J[SUP]6[/SUP], Yang L[SUP]3,[/SUP][SUP]4[/SUP], Guo W[SUP]3,[/SUP][SUP]4[/SUP], Hu S[SUP]3,[/SUP][SUP]4[/SUP], Hewage EK[SUP]3,[/SUP][SUP]4[/SUP], Chroneos ZC[SUP]3,[/SUP][SUP]4,[/SUP][SUP]7[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] Influenza A viruses cause life-threatening pneumonia and lung injury in the lower respiratory tract. Application of high GM-CSF levels prior to infection has been shown to reduce morbidity and mortality from pathogenic influenza infection in mice, but the mechanisms of protection and treatment efficacy have not been established.
[h=4]METHODS:[/h] Mice were infected intranasally with influenza A virus (PR8 strain). Supra-physiologic levels of GM-CSF were induced in the airways using the double transgenic GM-CSF (DTGM) or littermate control mice starting on 3 days post-infection (dpi). Assessment of respiratory mechanical parameters was performed using the flexiVent rodent ventilator. RNA sequence analysis was performed on FACS-sorted airway macrophage subsets at 8 dpi.
[h=4]RESULTS:[/h] Supra-physiologic levels of GM-CSF conferred a survival benefit, arrested the deterioration of lung mechanics, and reduced the abundance of protein exudates in bronchoalveolar (BAL) fluid to near baseline levels. Transcriptome analysis, and subsequent validation ELISA assays, revealed that excess GM-CSF re-directs macrophages from an "M1-like" to a more "M2-like" activation state as revealed by alterations in the ratios of CXCL9 and CCL17 in BAL fluid, respectively. Ingenuity pathway analysis predicted that GM-CSF surplus during IAV infection elicits expression of anti-inflammatory mediators and moderates M1 macrophage pro-inflammatory signaling by Type II interferon (IFN-γ).
[h=4]CONCLUSIONS:[/h] Our data indicate that application of high levels of GM-CSF in the lung after influenza A virus infection alters pathogenic "M1-like" macrophage inflammation. These results indicate a possible therapeutic strategy for respiratory virus-associated pneumonia and acute lung injury.


[h=4]KEYWORDS:[/h] Alveolar; Exudative; GM-CSF; Influenza; Interferon; Macrophage; Pneumonia; RNA-seq

PMID: 29304863 PMCID: PMC5756339 DOI: 10.1186/s12931-017-0708-5
Free PMC Article
 
Back
Top Bottom